Mon Nov 24 14:12:01 UTC 2025: Okay, here’s a summary and a news article based on the provided text:
Summary:
Gavi, the Vaccine Alliance, and UNICEF have reached an agreement to make the R21/Matrix-M malaria vaccine significantly more accessible and affordable. This deal, facilitated by Gavi and executed by UNICEF, aims to save up to $90 million over five years, allowing for the vaccination of nearly seven million more children against malaria. The price per dose will drop to $2.99. Malaria vaccines, including R21/Matrix-M and RTS,S/AS01, have been prequalified and recommended by the WHO and have shown to reduce malaria cases by more than half during initial trials. Over 40 million malaria vaccine doses have already been administered in 24 African countries with the highest malaria burden. UNICEF, the world’s largest vaccine buyer, plays a key role in securing the best possible prices for vaccines.
News Article:
Affordable Malaria Vaccine Deal to Protect Millions More Children
NEW DELHI/UNITED NATIONS – November 24, 2025 – A landmark agreement between Gavi, the Vaccine Alliance, and UNICEF will drastically increase access to and affordability of the R21/Matrix-M malaria vaccine, potentially saving millions of young lives across Africa.
The deal, announced today, will see the price of the vaccine drop to $2.99 per dose, unlocking significant savings for Gavi and partner countries. The estimated $90 million in savings will be reinvested to purchase an additional 30 million doses of the vaccine, enabling nearly seven million more children to be fully vaccinated against the deadly disease over the next five years.
Malaria remains a major public health threat, particularly in Africa, where it accounts for over 70% of the global burden. Both the R21/Matrix-M vaccine (co-developed by the University of Oxford and Serum Institute of India) and the RTS,S/AS01 vaccine (developed by GlaxoSmithKline (GSK), PATH and partners) have been prequalified by the World Health Organization (WHO) and have demonstrated significant efficacy in clinical trials. The vaccines are safe and effective and are recommended by WHO to prevent malaria in children. Initial data showed that both vaccines reduced malaria cases by more than half after the first year of vaccination.
Gavi facilitates the procurement, logistics, market shaping and integration of malaria vaccines into national immunisation programmes. So far, over 40 million doses of malaria vaccines have been delivered through the Gavi malaria vaccination programme and are now part of routine immunisation in 24 African countries with the highest malaria burden.
“This agreement is a game-changer in our fight against malaria,” said a Gavi spokesperson. “By making these life-saving vaccines more affordable, we can protect millions more children and move closer to eliminating this devastating disease.”
UNICEF, the world’s largest buyer of vaccines, is playing a critical role in negotiating favorable prices with manufacturers. The organization delivers nearly three billion vaccine doses every year.
The lower price is expected to take effect within approximately one year. This agreement marks a significant step towards a malaria-free future for millions of children across the globe.
First Piper 